APA (7th ed.) Citation

N, N., M, S., A, C., J, N., S, T., C, Q., . . . JP, M. (2021). Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Scientific reports, 11(1), 3173. https://doi.org/10.1038/s41598-021-82762-8

Chicago Style (17th ed.) Citation

N, Nagot, et al. "Growth, Clinical and Neurodevelopmental Outcomes at School Age Are Similar for Children Who Received 1-year Lamivudine or Lopinavir/ritonavir HIV Prophylaxis in Early Life." Scientific Reports 11, no. 1 (2021): 3173. https://doi.org/10.1038/s41598-021-82762-8.

MLA (9th ed.) Citation

N, Nagot, et al. "Growth, Clinical and Neurodevelopmental Outcomes at School Age Are Similar for Children Who Received 1-year Lamivudine or Lopinavir/ritonavir HIV Prophylaxis in Early Life." Scientific Reports, vol. 11, no. 1, 2021, p. 3173, https://doi.org/10.1038/s41598-021-82762-8.